文献速递免疫规划卫生政策与健康促进

西班牙60岁以上成人使用20价抗肺炎球菌疫苗(PCV20)的成本-效用分析

Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
PubMed 文献 · Vaccine · 2023-07-20

在西班牙60岁以上成人中构建10年周期马尔可夫模型,比较PCV20与PCV15序贯PPV23策略。

要点

  • 在西班牙60岁以上成人中,PCV20较PCV15序贯PPV23为优势方案(更有效且更便宜)。
  • PCV20避免IPD 2161例、NBP 19470例和死亡3396例。

核心结论

  • 在西班牙60岁以上成人中,接种一剂PCV20较PCV15序贯PPV23方案更有效且更便宜(优势方案)。

研究设计与样本

  • 马尔可夫模型,年度周期,时间跨度10年,分析人群按年龄和风险组分层。
  • 对照策略为PCV15序贯一剂PPV23。
  • 基础病例分析从国家卫生系统(NHS)角度纳入直接成本(2018年欧元),对未来成本和结局贴现3%。
  • 替代情景探索较短时间跨度(5年)、社会视角和其他可用疫苗接种策略。
  • 所有参数和假设由专家小组验证,并进行确定性和概率敏感性分析(PSA)评估模型稳健性。

主要发现

  • PCV20疫苗接种避免IPD 2161例、NBP 19470例和死亡3396例。
  • 根据PSA,PCV20较PCV15序贯PPSV23方案具成本效用的概率为100%。

关键数值与推荐

  • 基础病例分析贴现率3%,直接成本以2018年欧元计。
  • PCV20避免IPD 2161例、NBP 19470例和死亡3396例。
  • PSA显示PCV20具成本效用的概率为100%。

临床怎么用

  • 在西班牙60岁以上成人中,接种一剂PCV20较PCV15序贯PPV23方案更有效且更便宜(优势方案)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcalpneumonia (NBP) and invasive pneumococcal disease (IPD). METHODS: A Markov model, with annual cycles and a time horizon of 10 years was used. The analysis population was stratified by age and risk groups. The comparator was the sequential vaccination with the 15-valent pneumococcal conjugate vaccine (PCV15) followed by one dose of the pneumococcal polysaccharide vaccine (PPV23). The base case analysis was performed from the National Healthcare System (NHS) perspective including direct costs (€2018) and applying a discount of 3% to future costs and outcomes. Alternative scenarios explored a shorter time horizon (5 years), the societal perspective and other available vaccination strategies. All the parameters and assumptions were validated by a panel of experts. To evaluate the robustness of the model, deterministic and probabilistic sensitivity analyses (PSA) were carried out. RESULTS: The results of the study showed that the vaccination strategy with PCV20 is a dominant option compared to the sequential regimen (PCV15 + PPSV23), resulting in direct cost savings of €85.7 M over 10 years, with a small increase in quality-adjusted life years (QALYs). PCV20 vaccination avoided 2,161 cases of IPD, 19,470 of NBP and 3,396 deaths and according to the PSA, the probability of PCV20 being cost-effective compared to a sequential regimen (PCV15 + PPSV23) was 100%. CONCLUSIONS/RECOMMENDATIONS: In the Spanish adult population older than 60 years, the vaccination strategy with one dose of PCV20 is more effective and less expensive (dominant) than vaccination with a sequential schedule with PCV15 and PPSV23.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cantarero D, Ocaña D, Onieva-García MÁ, et al. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain. Vaccine. 2023. PMID: 37479615. doi:10.1016/j.vaccine.2023.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。